Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Short communication

Vol. 141 No. 3940 (2011)

Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets

  • Marcel Bruggisser
  • Michael Bodmer
  • Matthias E. Liechti
DOI
https://doi.org/10.4414/smw.2011.13267
Cite this as:
Swiss Med Wkly. 2011;141:w13267
Published
26.09.2011

Summary

BACKGROUND:Non-medical use of methylphenidate is increasing. Little is known about potential acute medical complications associated with recreational use of methylphenidate.

STUDY AIM: To identify medical problems associated with methylphenidate abuse.

METHODS: Retrospective case series of methylphenidate abuse cases presenting to an inner city emergency department.

RESULTS: We identified 14 cases of methylphenidate abuse between 2003 and 2010. Ten of these patients abused methylphenidate alone while four co-ingested other drugs, mainly alcohol. The route of ingestion was oral in nine patients, nasal in one and intravascular in four. Severe toxicity was exclusively observed in users who injected the drug. Two cases involved accidental intra-arterial injection and resulted in tissue necrosis leading to the amputation of a forearm and of fingertips, respectively. Clinical findings in the non-serious cases included mild to moderate symptoms and signs of sympathetic nervous stimulation such as agitation, tachycardia, hypertension, anxiety, hallucination, headache, tremor and dizziness. Nine of the fourteen patients were taking methylphenidate as a prescribed drug. Eight patients were former or current multiple substance abusers.

CONCLUSION: Methylphenidate misuse is not a significant burden for emergency departments in Switzerland. Oral and nasal administration of methylphenidate did not result in severe toxicity. However, injection of crushed methylphenidate pills lead to serious local toxicity. Most patients with methylphenidate abuse had a prescription for the drug indicating deviation from medical use. A history of multiple substance use may be a risk factor for non-medical use of methylphenidate.

References

  1. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84:135–43.
  2. Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42:288–94.
  3. Kostka R, Monego R, Rüegg S, Suter D, Zeltner C. Monitoringbericht Drogen und Sucht 2010. Zurich, Switzerland: Stadt Zürich, 2010.
  4. Bruggisser M, Ceschi A, Bodmer M, Wilks MF, Kupferschmidt H, Liechti ME. Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997–2009. Swiss Med Wkly. 2010;140:w13115.
  5. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106.
  6. Forrester MB. Methylphenidate abuse in Texas, 1998–2004. J Toxicol Environ Health A. 2006;69:1145–53.
  7. Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Subst Abus. 2002;23:165–9.
  8. Massello W, 3rd, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci. 1999;44:220–1.
  9. Garland EJ. Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry. 1998;37:1242–3.
  10. Persson HE, Sjoberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–13.
  11. Klampfl K, Quattlander A, Burger R, Pfuhlmann B, Warnke A, Gerlach M. Case report: intoxication with high dose of long-acting methylphenidate (Concerta((R))) in a suicidal 14-year-old girl. Atten Defic Hyperact Disord. 2010;2:221–4.
  12. Elenbaas RM, Waeckerie JF, McNabney WK. Abscess formation as a complication of parenteral methylphenidate abuse. JACEP. 1976;5:977–80.
  13. Hahn HH, Schweid AI, Beaty HN. Complications of injecting dissolved methylphenidate tablets. Arch Intern Med. 1969;123:656–9.
  14. Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol. 1972;3:67–70.
  15. Thalhammer C, Aschwanden M, Kliem M, Sturchler M, Jager KA. Acute ischemia after intraarterial drug injection. Dtsch Med Wochenschr. 2004;129:2405–8.
  16. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68:854–60.
  17. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456–63.
  18. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol. 2001;9:59–73.
  19. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245–58.
  20. Sevak RJ, Stoops WW, Hays LR, Rush CR. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther. 2009;328:1007–18.
  21. Rush CR, Essman WD, Simpson CA, Baker RW. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol. 2001;21:273–86.
  22. Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend. 2003;71:179–86.
  23. Lile JA, Stoops WW, Allen TS, Glaser PE, Hays LR, Rush CR. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology. (Berl) 2004;171:441–9.
  24. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther. 1995;57:356–65.
  25. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha KK. Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:213–20.
  26. Jaffe SL. Failed attempts at intranasal abuse of Concerta. J Am Acad Child Adolesc Psychiatry. 2002;41:5.
  27. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408–14.
  28. Bright MG. Abuse of medications employed for the treatement of ADHD: results from a lage-scale community survey. Medscape J Med. 2008;10:111.
  29. Ciccone PE. Attempted abuse of concerta. J Am Acad Child Adolesc Psychiatry. 2002;41:756.
  30. Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, et al. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. (Phila) 2007;45:737–52.

Most read articles by the same author(s)